+ More Filters

Reset Filters

Title

Funding Organization

Funding Type

Eligible Country

Deadline

Other (Select all that apply)

Show Expired Programs

Show Verified Programs

Not Verified

ADDF-Harrington Scholar Program

Alzheimer's Drug Discovery Foundation

Average Award

The award typically entails up to $600,000 over 2 years with dedicated support for milestone-driven projects from a team of industry veterans with capabilities that include medicinal chemistry, pharmacology & toxicology, and business development. The expertise of each team is tailored to the specific needs of the project during the two-year award period.

DEADLINES

Letter of Intent: (Extended) June 9, 2025, 5:00 PM EDT
Full Proposal: August 18, 2025, 5:00 PM EDT

Award decisions are anticipated by March 2026.

Funding Priorities

Drug Targets
The 2026 ADDF-Harrington Scholar RFP places high priority on targets related to emerging therapeutic areas for dementia, particularly:

Proteostasis (including autophagy, lysosomal biogenesis, proteasomal degradation, post-translational modification associated with proteostasis, protein folding/misfolding, ER stress, extracellular clearance)
Senescence (including cells that have halted division, shifted towards a secretory phenotype, altered morphology and epigenetics, and decreased apoptosis)

AI Based Application Success Predictor

🎯 1. Alignment with ADDF’s Venture-Philanthropy Model

ADDF functions like a venture fund: when supporting academia, they expect a share in any commercial returns; with biotech, they may take equity, royalties, or convertible notes 

Demonstrate a clear commercial path—composition-of-matter IP or novel therapeutic modalities are prioritized 

🧪 2. Strong Scientific Rationale & Innovation

The Drug Development RFP targets IND-enabling studies and early-phase clinical trials (Phase 0–2a), especially for drugs with novel mechanisms—excluding traditional anti-amyloid or cholinesterase inhibitors 

Applicants must justify:

The novelty of the mechanism

Genetic or human biology support

Biomarker linkages and pathway to demonstrate target engagement

📅 3. Feasible, Milestone-Based Plan

Multi-year grants (up to max ~$5M) require IND-enabling studies (toxicology, GMP production) or early human trials with measurable biomarker and clinical endpoints 

Include well-structured milestones, timelines, and demonstrate ability to recruit subjects and engage biostatisticians early 

👥 4. Team Strength & Collaboration

ADDF looks for strong teams combining scientific, clinical, regulatory, and business expertise; partnerships with CROs are encouraged 

For biotechs, the business review board evaluates management, IP, and commercial viability 

💸 5. Budgeting & Cost Management

Only direct costs are allowed (e.g., personnel, consumables, small equipment ≤ $2.5K); no indirect costs 

Grant amounts vary by stage; up to $5M is possible, but budget must align with milestones

🔁 6. Multi-Stage Review & Responsiveness

Process includes LOI → invited full proposal → iterative review by scientific and business panels 

Therapeutics applicants may resubmit up to two times addressing critiques point-by-point 

🔬 7. Support Beyond Funding

ADDF invests in non-financial support: expert guidance on preclinical/clinical strategy, regulatory affairs, partnership-building 

They also fund diagnostics accelerators, like the Biomarker Observatory, supporting blood, neuroimaging, and digital biomarker development 

✅ Summary Table

Predictor	What to Do
Business alignment	Showcase IP/commercial path and readiness for venture-philanthropy model
Scientific novelty and rigor	Propose a biomarker-supported, non-amyloid mechanism with strong evidence
Milestone-based feasibility	Include clear, measurable research milestones and timelines
Collaborative team structure	Combine scientific, clinical, regulatory, and business expertise
Direct-cost budgeting	Build precise budgets (no indirects or travel), aligned with milestones
Iterative submission planning	Prepare LOI, full proposal, and be ready to resubmit based on ADDF feedback
Non-financial support utilization	Leverage mentorship, networking, and diagnostic platform resources

🚀 Pro Tips to Boost Your Proposal

Start with LOI clarity: define the novel mechanism, target, biomarkers, and scale.

Line up partnerships: include CROs or biotech collaborators early.

Detail your clinical/IND plan: incorporate biostatistics, subject recruitment, regulatory path.

Budget for milestones: base funding tranches on deliverables.

Engage with ADDF: reach out if your project fits the RFP or needs feedback.

Plan resubmissions: prepare to refine based on board input.

Specialties

Neurosciences

Eligibility Requirements

Academic investigators at accredited medical centers, research institutions, and universities in the United States, Canada and United Kingdom only are eligible to apply.
Lead investigator must have an MD, a PhD, or equivalent.
Proposals should show potential to advance discovery into meaningful therapeutics to treat, prevent, slow, or reverse Alzheimer’s disease or related dementias (vascular dementia, frontotemporal dementia, Lewy Body dementia, LATE etc).
Team should possess intellectual property (IP) or have potential for novel IP that has not yet been licensed to a for-profit entity.
Researchers working on drug development programs that are relevant to but not presently focused on the Alzheimer’s field are strongly encouraged to apply.

Eligible Countries:

Canada

United Kingdom

United States

Sponsor Details

Sponsor Institute/Organizations: Alzheimer's Drug Discovery Foundation

Sponsor Type: Corporate/Non-Profit

Address: 57 West 57th Street, Suite 904 New York, NY 10019 info@alzdiscovery.org 212.901.8000

Legal & Affiliation Disclaimer

Affiliation Disclaimer: Trialect operates independently and is not affiliated with, endorsed by, or supported by any sponsors or organizations posting on the GrantsBoard platform. As an independent aggregator of publicly available funding opportunities, Trialect provides equal access to information for all users without endorsing any specific funding source, content, organization, or sponsor. Trialect assumes no responsibility for the content posted by sponsors or third parties.

Subscription Disclaimer: Upon logging into Trialect, you may choose to SUBSCRIBE to GrantsBoard for timely notifications of funding opportunities and to access exclusive benefits, such as priority alerts, reminders, personalized recommendations, and additional application support. However, users are advised to contact sponsors directly for any questions and are not required to subscribe to engage with funding opportunities.

Content Ownership and Copyright Disclaimer: Trialect respects the intellectual property rights of all organizations and individuals. All content posted on GrantsBoard is provided solely for informational purposes and remains the property of the original owners. Trialect does not claim ownership of, nor does it have any proprietary interest in, content provided by third-party sponsors. Users are encouraged to verify content and ownership directly with the posting sponsor.

Fair Use Disclaimer: The information and content available on GrantsBoard are compiled from publicly accessible sources in alignment with fair use principles under U.S. copyright law. Trialect serves as an aggregator of this content, offering it to users in good faith and with the understanding that it is available for public dissemination. Any organization or individual who believes their intellectual property rights have been violated is encouraged to contact us for prompt resolution.

Third-Party Posting Responsibility Disclaimer: Trialect is a neutral platform that allows third-party sponsors to post funding opportunities for informational purposes only. Sponsors are solely responsible for ensuring that their postings comply with copyright, trademark, and other intellectual property laws. Trialect assumes no liability for any copyright or intellectual property infringements in third-party content and will take appropriate action to address any substantiated claims.

Accuracy and Verification Disclaimer: Trialect makes no warranties regarding the accuracy, completeness, or reliability of the information provided by sponsors. Users are advised to verify the details of any funding opportunity directly with the sponsor before taking action. Trialect cannot be held liable for any discrepancies, omissions, or inaccuracies in third-party postings.

Notice and Takedown Policy: Trialect is committed to upholding copyright law and protecting the rights of intellectual property owners. If you believe that content on GrantsBoard infringes your copyright or intellectual property rights, please contact us with detailed information about the claim. Upon receipt of a valid notice, Trialect will promptly investigate and, where appropriate, remove or disable access to the infringing content.

View Funding Opportunity